Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer
Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.
Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
- NLRP3 is a promising target with a well-validated role in various inflammatory disease
- Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release
- In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduction in systemic inflammation
Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
- Scientific Advisory Board (SAB) to offer expert guidance and direction for the development of lead compound SECN-15 and the Company’s oncology pipeline
- Dr. Alexander M.M. Eggermont convened SAB as of July 1, 2024 together with Prof. Dr. Alfred Zippelius, who has been an advisor to Secarna since 2016
JP Morgan 43rd Annual Healthcare Conference 2025
18th Annual European Life Sciences CEO Forum (Sachs ELSF)
Latest News & Events
Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer
Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer. He has served as the Company’s Chief Business Officer since June 2023. Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition.
Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3
- NLRP3 is a promising target with a well-validated role in various inflammatory disease
- Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release
- In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduction in systemic inflammation
Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
- Scientific Advisory Board (SAB) to offer expert guidance and direction for the development of lead compound SECN-15 and the Company’s oncology pipeline
- Dr. Alexander M.M. Eggermont convened SAB as of July 1, 2024 together with Prof. Dr. Alfred Zippelius, who has been an advisor to Secarna since 2016